Cost and cost-effectiveness of switching from d4T or AZT to a TDF-based first-line regimen in a resource-limited setting in rural lesotho

Journal of Acquired Immune Deficiency Syndromes

Volumn 58, Issue 3, 2011, Pages

  Jouquet, Guillaume ^a   Bygrave, Helen ^a   Kranzer, Katharina ^b   Ford, Nathan ^a,c   Gadot, Laurent ^a   Lee, Janice ^a   Hilderbrand, Katherine ^a   Goemaere, Eric ^a   Vlahakis, Natalie ^a   Trivino, Laura ^a   Makakole, Lipontso ^d   Cleary, Susan ^c  

^a MÉDECINS SANS FRONTIÈRES   (Switzerland)

^b LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^c UNIVERSITY OF CAPE TOWN   (South Africa)

^d Scott Hospital   (Lesotho)

Author keywords

cost effectiveness; Stavudine; Tenofovir; toxicity

Indexed keywords

COTRIMOXAZOLE; EFAVIRENZ; LAMIVUDINE; NEVIRAPINE; STAVUDINE; TENOFOVIR; ZIDOVUDINE;

ABDOMINAL PAIN; ANEMIA; ANTIBIOTIC PROPHYLAXIS; ARTICLE; CD4 LYMPHOCYTE COUNT; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; CREATININE CLEARANCE; DRUG COST; DRUG EFFICACY; DRUG MANUFACTURE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; DYSPNEA; FEMALE; FOLLOW UP; HEALTH CARE COST; HEALTH CARE UTILIZATION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; LABORATORY TEST; LACTIC ACIDOSIS; LESOTHO; LIPODYSTROPHY; MAJOR CLINICAL STUDY; MALE; MIXED INFECTION; NEUROPATHY; OUTCOME ASSESSMENT; PATIENT COUNSELING; PRESCRIPTION; PRIORITY JOURNAL; QUALITY OF LIFE; RURAL AREA; SIDE EFFECT; TUBERCULOSIS; VISUAL ANALOG SCALE; VOMITING; WEIGHT REDUCTION;

ADENINE; ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; COST-BENEFIT ANALYSIS; DEVELOPING COUNTRIES; FEMALE; HEALTH CARE COSTS; HIV INFECTIONS; HUMANS; LESOTHO; MALE; MIDDLE AGED; PHOSPHONIC ACIDS; PREGNANCY; RURAL POPULATION; STAVUDINE; ZIDOVUDINE;

EID: 80054901647     PISSN: 15254135     EISSN: 10779450     Source Type: Journal    
DOI: 10.1097/QAI.0b013e31822a9f8d     Document Type: Article

References (19)

1. Anon. Rapid Advice: Antiretroviral Therapy for HIV Infection in Adults and Adolescents. Geneva: World Health Organization; 2009.
2. Alcorn K. European Medicines Agency: d4T to be used only in last resort side-effects. Aidsmap. February 21, 2011
3. Ford N, Calmy A. Improving first-line antiretroviral therapy in resourcelimited settings. Curr Opin HIV AIDS. 2010;5:38-47.
4. Parienti JJ, Bangsberg DR, Verdon R, et al. Better adherence with oncedaily antiretroviral regimens: a meta-analysis. Clin Infect Dis. 2009;48: 484-488.
5. Hirnshall G. The New WHO Recommendations for HIV Treatment. Geneva: World Health Organization; 2010.
6. Bender MA, Kumarasamy N, Mayer KH, et al. Cost-effectiveness of tenofovir as first-line antiretroviral therapy in India. Clin Infect Dis. 2010; 50:416-425.
7. Rosen S, Long L, Fox M, et al. Cost and cost-effectiveness of switching from stavudine to tenofovir in first-line antiretroviral regimens in South Africa. J Acquir Immune Defic Syndr. 2008;48:334-344.
8. Cohen R, Lynch S, Bygrave H, et al. Antiretroviral treatment outcomes from a nurse-driven, community-supported HIV/AIDS treatment programme in rural Lesotho: observational cohort assessment at two years. J Int AIDS Soc. 2009;12:23.
9. Drummond MF, Sculpher MJ, Torrance GW, et al. Methods for the Economic Evaluation of Health Care Programmes. 3rd ed. Oxford: Oxford University Press; 2005.
10. Briggs AH. Handling uncertainty in economic evaluation and presenting the results. In: Drummond M, McGuire A, eds. Economic Evaluation in Health Care: Merging Theory With Practice. Oxford: Oxford University Press; 2001.
11. Gallant JE, Staszewski S, Pozniak AL, et al. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-näve patients: a 3-year randomized trial. JAMA. 2004;292:191-201. (Pubitemid 38917996)
12. Davidson I, Beardsell H, Smith B, et al. The frequency and reasons for antiretroviral switching with specific antiretroviral associations: the SWITCH study. Antiviral Res. 2010;86:227-229.
13. Bygrave H, Ford N, van Cutsem G, et al. Implementing a tenofovirbased first-line regimen in rural Lesotho: clinical outcomes and toxicities after two years. J Acquir Immune Defic Syndr. 2010;56: e75-e78.
14. Rosen S MK, Mazimba A, Long L, et al. Net cost of switching from stavudine to tenofovir in first line antiretroviral therapy in Zambia. In: 5th IAS Conference on HIV Pathogenesis, Treatment, and Prevention; Cape Town, South Africa; July 19-22 2009. Abstract MOPED015.
15. Moore S, Myint MM, Galau NH. Advantages of low-cost generic tenofovir instead of D4T for first-line antiretroviral therapy in Burma: a 2-year experience. Aids. 2010;24:1606-1607.
16. Sanchez-de la Rosa R, Herrera L, Moreno S. Cost-effectiveness analysis of emtricitabine/tenofovir versus lamivudine/zidovudine, in combination with efavirenz, in antiretroviral-naive, HIV-1-infected patients. Clin Ther. 2008;30:372-381. (Pubitemid 351474379)
17. Amoroso A, Sheneberger R, Edozien A, et al. Antiretroviral-associated drug toxicities leading to a switch in medication: experience in Uganda, Kenya, and Zambia. In: 14th Conference on Retroviruses and Opportunistic Infections; Los Angeles; February 25-28 2007. Abstract 789.
18. Boulle A, Orrel C, Kaplan R, et al. International Epidemiological Databases to Evaluate Aids in Southern Africa Collaboration. Substitutions due to antiretroviral toxicity or contraindication in the first 3 years of antiretroviral therapy in a large South African cohort. Antivir Ther. 2007;12:753-760. (Pubitemid 47235489)
19. Anon. Untangling the Web of Antiretroviral Price Reductions. 14th ed. Geneva: Médecins Sans Froniéres; 2011.